APO RESEARCH · REPORT
Checkpoint Inhibitors for Treating Cancer
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Product & engineering
Understand the product.
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
Selected research
Market Structure
Global Checkpoint Inhibitors for Treating Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
This report provides an overview of the global Checkpoint Inhibitors for Treating Cancer market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Checkpoint Inhibitors for Treating Cancer and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Checkpoint Inhibitors for Treating Cancer sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Checkpoint Inhibitors for Treating Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.
Checkpoint Inhibitors for Treating Cancer Segment by Company
Bristol-Myers Squibb(BMS)
Merck
Roche
Checkpoint Inhibitors for Treating Cancer Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Checkpoint Inhibitors for Treating Cancer Segment by Application
Melanoma Treatment
Bladder Cancer Treatment
Other
Checkpoint Inhibitors for Treating Cancer Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Checkpoint Inhibitors for Treating Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Checkpoint Inhibitors for Treating Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Checkpoint Inhibitors for Treating Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Checkpoint Inhibitors for Treating Cancer market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Checkpoint Inhibitors for Treating Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Checkpoint Inhibitors for Treating Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Checkpoint Inhibitors for Treating Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- PD-1 Inhibitors
- PD-L1 Inhibitors
- CTLA-4 Inhibitors
Applications
- Melanoma Treatment
- Bladder Cancer Treatment
- Other
Companies covered
- Bristol-Myers Squibb(BMS)
- Merck
- Roche
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Checkpoint Inhibitors for Treating Cancer Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Checkpoint Inhibitors for Treating Cancer Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Checkpoint Inhibitors for Treating Cancer Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Checkpoint Inhibitors for Treating Cancer Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Checkpoint Inhibitors for Treating Cancer Market Dynamics
- 2.1 Checkpoint Inhibitors for Treating Cancer Industry Trends
- 2.2 Checkpoint Inhibitors for Treating Cancer Industry Drivers
- 2.3 Checkpoint Inhibitors for Treating Cancer Industry Opportunities and Challenges
- 2.4 Checkpoint Inhibitors for Treating Cancer Industry Restraints
3 Checkpoint Inhibitors for Treating Cancer Market by Manufacturers
- 3.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2021-2026)
- 3.2 Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers (2021-2026)
- 3.3 Global Checkpoint Inhibitors for Treating Cancer Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Checkpoint Inhibitors for Treating Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Checkpoint Inhibitors for Treating Cancer Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Checkpoint Inhibitors for Treating Cancer Manufacturers, Product Type & Application
- 3.7 Global Checkpoint Inhibitors for Treating Cancer Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Checkpoint Inhibitors for Treating Cancer Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Checkpoint Inhibitors for Treating Cancer Players Market Share by Revenue in 2025
- 3.8.3 2025 Checkpoint Inhibitors for Treating Cancer Tier 1, Tier 2, and Tier 3
4 Checkpoint Inhibitors for Treating Cancer Market by Type
- 4.1 Checkpoint Inhibitors for Treating Cancer Type Introduction
- 4.1.1 PD-1 Inhibitors
- 4.1.2 PD-L1 Inhibitors
- 4.1.3 CTLA-4 Inhibitors
- 4.2 Global Checkpoint Inhibitors for Treating Cancer Sales by Type
- 4.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2021-2032)
- 4.2.3 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2021-2032)
- 4.3 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type
- 4.3.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2021-2032)
- 4.3.3 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2021-2032)
5 Checkpoint Inhibitors for Treating Cancer Market by Application
- 5.1 Checkpoint Inhibitors for Treating Cancer Application Introduction
- 5.1.1 Melanoma Treatment
- 5.1.2 Bladder Cancer Treatment
- 5.1.3 Other
- 5.2 Global Checkpoint Inhibitors for Treating Cancer Sales by Application
- 5.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2021-2032)
- 5.2.3 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2021-2032)
- 5.3 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application
- 5.3.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2021-2032)
- 5.3.3 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2021-2032)
6 Global Checkpoint Inhibitors for Treating Cancer Sales by Region
- 6.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Checkpoint Inhibitors for Treating Cancer Sales by Region (2021-2032)
- 6.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Region (2021-2026)
- 6.2.2 Global Checkpoint Inhibitors for Treating Cancer Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Checkpoint Inhibitors for Treating Cancer Revenue by Region
- 7.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Region
- 7.1.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Region (2021-2026)
- 7.1.3 Global Checkpoint Inhibitors for Treating Cancer Revenue by Region (2027-2032)
- 7.1.4 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Checkpoint Inhibitors for Treating Cancer Revenue (2021-2032)
- 7.2.2 North America Checkpoint Inhibitors for Treating Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Checkpoint Inhibitors for Treating Cancer Revenue (2021-2032)
- 7.3.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue (2021-2032)
- 7.4.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Bristol-Myers Squibb(BMS)
- 8.1.1 Bristol-Myers Squibb(BMS) Company Information
- 8.1.2 Bristol-Myers Squibb(BMS) Business Overview
- 8.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product Portfolio
- 8.1.5 Bristol-Myers Squibb(BMS) Recent Developments
- 8.2 Merck
- 8.2.1 Merck Company Information
- 8.2.2 Merck Business Overview
- 8.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Merck Checkpoint Inhibitors for Treating Cancer Product Portfolio
- 8.2.5 Merck Recent Developments
- 8.3 Roche
- 8.3.1 Roche Company Information
- 8.3.2 Roche Business Overview
- 8.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Roche Checkpoint Inhibitors for Treating Cancer Product Portfolio
- 8.3.5 Roche Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Checkpoint Inhibitors for Treating Cancer Value Chain Analysis
- 9.1.1 Checkpoint Inhibitors for Treating Cancer Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Checkpoint Inhibitors for Treating Cancer Production Mode & Process
- 9.2 Checkpoint Inhibitors for Treating Cancer Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Checkpoint Inhibitors for Treating Cancer Distributors
- 9.2.3 Checkpoint Inhibitors for Treating Cancer Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst